Using an elaborated cleavable linker, trastuzumab deruxtecan shows a so-called bystander killer effect and is assumed to target tumor cells with HER2 overexpression as well as BC cells with low HER2 expression (Beck et al. 2010; Gampenrieder et al. 2021). Here, ERBB2 is linked to breast cancer.